000			01915na a2200277 4500
999			_c4143 _d4143
003			PC4143
005			20181121085513.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCastellano Tortajada, Gregorio _91207 _eAparato Digestivo
245	0	0	_aFactors associated with early virological response to peginterferon-alpha-2a/ribavirin in chronic hepatitis C. _h[artículo]
260			_bWorld Journal of Gastroenterology, _c2013
300			_a19(12):1943-52.
500			_aFormato Vancouver: García-Samaniego J, Romero M, Granados R, Alemán R, Jorge Juan M, Suárez D et al. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C. World J Gastroenterol. 2013 Mar 8;19(12):1943-52.
501			_aPMID: 23569340
504			_aContiene 43 referencias
520			_aAIM: To evaluate the impact of sociodemographic/clinical factors on early virological response (EVR) to peginterferon/ribavirin for chronic hepatitis C (CHC) in clinical practice. METHODS: We conducted a multicenter, cross-sectional, observational study in Hepatology Units of 91 Spanish hospitals. CHC patients treated with peginterferon alpha-2a plus ribavirin were included. EVR was defined as undetectable hepatitis C virus (HCV)-ribonucleic acid (RNA) or >= 2 log HCV-RNA decrease after 12 wk of treatment. A bivariate analysis of sociodemographic and clinical variables associated with EVR was carried out. Independent factors associated with an EVR were analyzed using a multiple regression analysis that included the following baseline demographic and clinical variables: age (<= 40 years vs > 40 years), gender, race, educational level, marital status and family status, weight, alcohol and tobacco consumption, source of HCV infection, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, and gamma glutamyl transpeptidase (GGT) (<= 85 IU/mL vs >
710			_9273 _aServicio de Medicina del Aparato Digestivo
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613110/ _yAcceso libre
942			_n0 _2ddc _cART